← All companies
#26 · fastest growing
NewLimit
Epigenetic reprogramming medicines that reverse cellular age — first clinical trials imminent.
Therapeutics that reprogram aged cells (starting with liver) toward younger functional states for metabolic, vascular and immune health.
Series C / clinical path
$435M Series C led by Founders Fund (Thrive, Greenoaks, Quiet, KP, Abstract, Nat Friedman/Daniel Gross, Valor, Lilly Ventures, Human Capital…)
Notable
- Prototype medicine reverses age in old human liver cells
- Accelerated timeline to first human trial (next year)
- Programs also targeting endothelial and T cells
Links
Loading prediction markets…
Map
Approximate HQ location (SF / Bay Area cluster).
View on growth map →